COR Company Profile and Key Details

NYSE : COR

Cencora

$352.16

22.19+6.72%

At Close 4:00 PM

69.85

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Cencora, Inc. (COR) stock surged +6.72%, trading at $352.16 on NYSE, up from the previous close of $329.97. The stock opened at $336.08, fluctuating between $332.99 and $362.35 in the recent session.

Stock Snapshot

329.97

Prev. Close

68.5B

Market Cap

332.985

Day Low

39.7

P/E Ratio

8.87

EPS (TTM)

18.14

Cash Flow per Share

336.08

Open

194.53M

Number of Shares

362.35

Day High

95.74%

Free Float in %

4.56

Book Value

2.88M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	336.08	362.35	332.99	352.16	2.88M
Feb 04, 2026	345.00	356.97	328.01	329.97	3.23M
Feb 03, 2026	362.72	366.15	361.75	361.75	1.39M
Feb 02, 2026	360.58	364.27	356.87	363.56	1.01M
Jan 30, 2026	351.54	359.48	349.49	359.22	1.23M
Jan 29, 2026	354.78	362.43	350.97	352.10	1.72M
Jan 28, 2026	354.33	355.79	346.52	350.54	851.52K
Jan 27, 2026	353.17	356.69	351.63	356.14	1.14M
Jan 26, 2026	355.00	357.10	353.60	355.51	900.2K
Jan 23, 2026	351.43	353.56	347.63	353.48	1.13M
Jan 22, 2026	356.14	356.51	351.02	352.47	1.12M
Jan 21, 2026	349.87	354.96	342.72	351.75	1.3M
Jan 20, 2026	354.73	358.95	349.94	350.67	884.76K
Jan 16, 2026	355.17	356.87	352.42	354.85	1.4M
Jan 15, 2026	349.55	355.75	349.11	355.35	1.08M
Jan 14, 2026	345.40	349.98	345.11	349.93	757.48K
Jan 13, 2026	344.54	349.02	342.78	345.88	1.16M
Jan 12, 2026	337.19	342.30	333.95	342.16	990.33K
Jan 09, 2026	334.31	339.47	333.79	335.69	916.92K
Jan 08, 2026	340.97	347.29	334.18	335.74	1.13M

Contact Details

Conshohocken, PA 19428-1800

United States

https://www.cencora.com 610 727 7000

About Company

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Stock Peers

MCK

135.8+16.52%

McKesson Corporation$957.80 CAH

20.33+9.83%

Cardinal Health, Inc.$227.18 ABC

-0.41-0.23%

AmerisourceBergen Corporation$179.98 PBH

-1.48-2.21%

Prestige Consumer Healthcare Inc.$65.55 GRDN

1.43+4.55%

Guardian Pharmacy Services, Inc.$32.87 OMI

0.22+8.94%

Owens & Minor, Inc.$2.68 ACH

-0.12-5.17%

Accendra Health, Inc.$2.20

Company Overview

Cencora, Inc. (NYSE:COR) closed at $352.16 USD, gaining $22.19 (6.72%) from the previous close of $329.97. The stock is currently mid-range between its 52-week high and low $237.71 and $377.54. With a market capitalization of about $68.50 billion, Cencora, Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.68). Key stats such as the average daily volume over the past year has been around 1.38 million shares, trading with heavier-than-usual volume. Headquartered in Conshohocken, PA, Cencora, Inc. operates in the Healthcare sector and the Medical - Distribution industry. Led by CEO Robert Mauch, the company employs approximately 47,000 people and listed since April 04, 1995. Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 0.49%, SMA50 1.28%, SMA200 11.88%). The stock’s 14-day RSI is 51.52 (neutral), while the ATR of 10.74 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -6.72% below its high and over 48.15% above its low. Average 10-day trading volume of 1.68 million shares is slightly above the 3-month average of 1.34 million, indicating heightened recent market interest.

Valuation Metrics

Cencora, Inc. trades at a P/E ratio of 42.15, slightly above the S&P 500 average, with a price-to-sales ratio of 0.21 and a price-to-book ratio of 35.9 reflecting a rich premium to book value. The P/FCF stands at 18.97, also above market averages. Compared to sector medians, Cencora, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Cencora, Inc. last paid a dividend of 2.25 per share, this equals a trailing yield of roughly 0.84%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $628.40. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 10.71% annually over the next five years. The latest quarter delivered EPS of $3.84. The next quarter is forecast at $4.86. Next year's EPS is expected at $9.39. Analyst sentiment is bullish. Analyst rating data shows there are 11 Strong Buy ratings, 5 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $440.00 to $274.00. The high target offers 24.94% upside. The low target suggests -22.19% downside. The mean target is $365.90. This offers 3.9% upside. Cencora, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 05, 2025, missed forecasts by 1.32%. The prior quarter beat by 3.9%. Over the last six quarters, Apple has recorded several small beats. These include 3.73% in July 31, 2024.

Shareholding & Insider Activity

Cencora, Inc. has 193.88 million shares outstanding. The public float is 185.61 million shares, elevated short interest at 5.45% of float. This equals 6.14 million shares. The short ratio is 4.56 days. Institutional investors hold 98.13% of the float. Insiders own 4.2%. Walgreens Boots Alliance, Inc. holds 12.57 million shares, COLLIS STEVEN H has 305.91 thousand shares and Szurek Paul E. has 242.35 thousand shares. Over the past six months, insider transactions show net selling. They sold 87.32 thousand shares across 12 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Cencora generated $321.33B in revenue, or $1.65K per share. Gross margin was 3.16%, operating margin 1.14%, and net profit margin 0.48%. Returns are modest, with ROA at 2.03% and ROE at 103.06%.
On valuation metrics, Cencora trades at a P/E of 42.15, P/S of 0.21 and P/B of 35.90. Liquidity is tight, with a current ratio of 0.92 and quick ratio of 0.51. Operationally, the company’s inventory turnover is 13.09 and cash conversion cycle is -7.94 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 4.15, supported by a cash flow-to-debt ratio of 0.54.

Quarterly Financial Highlights

For the quarter ended Sep 30, 2025, Cencora posted revenue of $321.33B, down slightly from $293.96B in the prior quarter. Gross profit was $10.14B (margin 3.16%). Operating income was $3.65B (margin 1.1%). Net income was$1.55B (EPS $8.02).
The company ended the quarter with $4.36B in cash and short-term investments, a total debt of $7.66B, and net debt of $3.30B. Total assets were $76.59B, with equity of $1.75B. Financials further reflected stability, with operating cash flow of $3.88B, free cash flow of $3.21B, and capital expenditures of - $667.98M.

Price Forecast & Outlook

Our AI price prediction model suggests that Cencora, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.35%, with price expected at $353.41 by February 19, 2026, within a range of $347.97 to $359.23 3-Month Outlook: Projected rise of 8.32%, reaching $381.46 by May 05, 2026, with a range of $375.38 to $386.91. 1-Year Outlook: Projected gain of 15.58%, with price at $407.02 by February 05, 2027, within a range of $400.78 to $413.47.

Key Takeaways

Cencora, Inc. (NYSE:COR) shares are flat 3.83% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cencora, Inc. trading at a premium to the broader market with a P/E of 42.15. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $283.11, suggesting -19.61% downside. Our AI forecast model points to short-term strength (0.35% over two weeks), a medium-term rise (8.32% over three months), and a longer-term gain (15.58% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Cencora, Inc. (COR) stock price?

Cencora, Inc. (NYSE: COR) stock price is $352.16 in the last trading session. During the trading session, COR stock reached the peak price of $362.35 while $332.99 was the lowest point it dropped to. The percentage change in COR stock occurred in the recent session was 6.72% while the dollar amount for the price change in COR stock was $22.19.

COR's industry and sector of operation?

The NYSE listed COR is part of Medical - Distribution industry that operates in the broader Healthcare sector. Cencora, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of COR?

No Data

How COR did perform over past 52-week?

COR's closing price is 48.15% higher than its 52-week low of $237.71 where as its distance from 52-week high of $377.54 is -6.72%.

How many employees does COR have?

Number of COR employees currently stands at 47,000.

Link for COR official website?

Official Website of COR is: https://www.cencora.com

How do I contact COR?

COR could be contacted at phone 610 727 7000 and can also be accessed through its website. COR operates from 1 West First Avenue, Conshohocken, PA 19428-1800, United States.

How many shares of COR are traded daily?

COR stock volume for the day was 2.88M shares. The average number of COR shares traded daily for last 3 months was 1.38M.

What is the market cap of COR currently?

The market value of COR currently stands at $68.50B with its latest stock price at $352.16 and 194.53M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	47000
Beta	0.67
Sales or Revenue	$321.33B
5Y Sales Change%	0.788%
Fiscal Year Ends	September
Sector	Healthcare
Industry	Medical - Distribution

COR Company Profile and Key Details

Cencora

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook